Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bariatric Surgery in Children. (BASIC)

25 augustus 2021 bijgewerkt door: Maastricht University Medical Center

The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery

Rationale:

In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.

The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)

Objective:

To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.

Study design:

Prospective randomised interventional study.

Study population:

Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.

Intervention:

Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions

Main study parameters/endpoints:

Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Limburg
      • Maastricht, Limburg, Nederland, 6202ZA
        • Maastricht University Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

14 jaar tot 16 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Aged 14 to 16
  • Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.

    * Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.

  • > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
  • Demonstrate decisional capacity

Exclusion Criteria:

  • Psychologically not suitable
  • Pre-menarche or bone age <15 years in boys
  • Obesity associated to other disorders such as hypothyroidism
  • Syndromal disorders such as Prader-Willi syndrome
  • Severe cardiorespiratory impairment (ASA class 3 or higher)
  • Insufficiently fluid in the Dutch language
  • Unwillingness to adhere to follow-up programmes

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Controlegroep
Control group will receive standard therapy consisting of combined lifestyle interventions.
Experimenteel: Laparoscopic adjustable gastric band
Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Weight
Tijdsspanne: 6 months
Weight loss, excess weight loss and loss of excess BMI.
6 months
Weight
Tijdsspanne: 12 months
Weight loss, excess weight loss and loss of excess BMI.
12 months
Weight
Tijdsspanne: 24 months
Weight loss, excess weight loss and loss of excess BMI.
24 months
Weight
Tijdsspanne: 36 months
Weight loss, excess weight loss and loss of excess BMI.
36 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Body composition
Tijdsspanne: 12 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
12 months
Pubertal development
Tijdsspanne: 6 months
Follow-up of hormonal status and Tanner stages.
6 months
Metabolic and endocrine changes
Tijdsspanne: 6 months
6 months
Inflammatory status
Tijdsspanne: 6 months
Measurement of serum inflammatory markers.
6 months
Cardiovascular abnormalities
Tijdsspanne: 6 months
6 months
Non-alcoholic fatty liver disease
Tijdsspanne: 6 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
6 months
Quality of life changes
Tijdsspanne: 6 months
6 months
Behaviour changes
Tijdsspanne: 6 months
Measuring impulsivity and positive reward dominance with a computer task.
6 months
Operative complications
Tijdsspanne: up to 36 months
Early and late complications are being monitored
up to 36 months
Effects on sleep architecture
Tijdsspanne: 6 months
6 months
Brain development
Tijdsspanne: 6 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
6 months
Body composition
Tijdsspanne: 24 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
24 months
Body composition
Tijdsspanne: 36 months
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
36 months
Pubertal development
Tijdsspanne: 12 months
Follow-up of hormonal status and Tanner stages.
12 months
Pubertal development
Tijdsspanne: 24 months
Follow-up of hormonal status and Tanner stages.
24 months
Pubertal development
Tijdsspanne: 36 months
Follow-up of hormonal status and Tanner stages.
36 months
Metabolic and endocrine changes
Tijdsspanne: 12 months
12 months
Metabolic and endocrine changes
Tijdsspanne: 24 months
24 months
Metabolic and endocrine changes
Tijdsspanne: 36 months
36 months
Inflammatory status
Tijdsspanne: 12 months
Measurement of serum inflammatory markers.
12 months
Inflammatory status
Tijdsspanne: 24 months
Measurement of serum inflammatory markers.
24 months
Inflammatory status
Tijdsspanne: 36 months
Measurement of serum inflammatory markers.
36 months
Cardiovascular abnormalities
Tijdsspanne: 12 months
12 months
Cardiovascular abnormalities
Tijdsspanne: 24 months
24 months
Cardiovascular abnormalities
Tijdsspanne: 36 months
36 months
Non-alcoholic fatty liver disease
Tijdsspanne: 12 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
12 months
Non-alcoholic fatty liver disease
Tijdsspanne: 24 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
24 months
Non-alcoholic fatty liver disease
Tijdsspanne: 36 months
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured. CCL-2 is used as a surrogate marker to assess liver disease.
36 months
Quality of life changes
Tijdsspanne: 12 months
12 months
Quality of life changes
Tijdsspanne: 24 months
24 months
Quality of life changes
Tijdsspanne: 36 months
36 months
Effects on sleep architecture
Tijdsspanne: 12 months
12 months
Effects on sleep architecture
Tijdsspanne: 24 months
24 months
Effects on sleep architecture
Tijdsspanne: 36 months
36 months
Behaviour changes
Tijdsspanne: 12 months
Measuring impulsivity and positive reward dominance with a computer task.
12 months
Behaviour changes
Tijdsspanne: 24 months
Measuring impulsivity and positive reward dominance with a computer task.
24 months
Behaviour changes
Tijdsspanne: 36 months
Measuring impulsivity and positive reward dominance with a computer task.
36 months
Brain development
Tijdsspanne: 12 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
12 months
Brain development
Tijdsspanne: 24 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
24 months
Brain development
Tijdsspanne: 36 months
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
36 months
Physical activity
Tijdsspanne: 6 months
Assessment of physical activity using a questionnaire and an accelerometer.
6 months
Physical activity
Tijdsspanne: 12 months
Assessment of physical activity using a questionnaire and an accelerometer.
12 months
Physical activity
Tijdsspanne: 24
Assessment of physical activity using a questionnaire and an accelerometer.
24
Physical activity
Tijdsspanne: 36 months
Assessment of physical activity using a questionnaire and an accelerometer.
36 months
Behavior towards food
Tijdsspanne: 6 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
6 months
Behavior towards food
Tijdsspanne: 12 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
12 months
Behavior towards food
Tijdsspanne: 24 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
24 months
Behavior towards food
Tijdsspanne: 36 months
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
36 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: LWE van Heurn, Professor, Maastricht University Medical Center
  • Hoofdonderzoeker: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
  • Hoofdonderzoeker: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 december 2011

Primaire voltooiing (Verwacht)

1 december 2022

Studie voltooiing (Verwacht)

1 december 2022

Studieregistratiedata

Eerst ingediend

22 juli 2010

Eerst ingediend dat voldeed aan de QC-criteria

29 juli 2010

Eerst geplaatst (Schatting)

30 juli 2010

Updates van studierecords

Laatste update geplaatst (Werkelijk)

26 augustus 2021

Laatste update ingediend die voldeed aan QC-criteria

25 augustus 2021

Laatst geverifieerd

1 augustus 2021

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • NL26279.068.09

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op Obesitas, morbide

Klinische onderzoeken op laparoscopic adjustable gastric band

3
Abonneren